About GenPhar
GenPhar is a Healthcare company based in Mount Pleasant (United States) founded in 1999 by Jian-Yun Dong. Vaccines and therapies for rare diseases are developed. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
GenPhar was founded in 1999 in Mount Pleasant, United States. Operations center on the biotechnology sector, where vaccines and therapies for rare diseases are developed. Emphasis is placed on biodefense, prophylactic, and therapeutic vaccines directed at dangerous viral diseases. The product line encompasses drug resistance testing, vaccine development, and cancer treatments, supporting advancements in medical countermeasures.
- Headquarters Mount Pleasant, United States
- Founders Jian-Yun Dong
- SectorsHealthcare
- Website genphar.com
- Social Facebook
- Latest Funding Round$2.18M (USD), Grant
Sep 2009
- Investors
Funding Insights of GenPhar
- Total Rounds 2
- Last Round Grant — $2.18M
- First Round $433,738
(Jul 2008)
- Investors Count 1
All 2 funding rounds of GenPhar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in GenPhar
GenPhar has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for GenPhar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GenPhar
1 people are tracked at GenPhar (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jian-Yun Dong | Founder | Leadership |
Complete people profiles for GenPhar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GenPhar
3 dated milestones of GenPhar across 10 years, from founding to its latest funding, stage changes and deals.
- Founded GenPhar is founded.
- Funding First funding round of $434K.
- Funding Latest funding round, Grant, of $2.2M.
Competitors of GenPhar
GenPhar has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of GenPhar
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GenPhar
Websites that share an audience with GenPhar (genphar.com).
Websites whose visitors overlap most with GenPhar. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| intercell.com | 100% | View details | |||
| vaxgen.com | 100% | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as GenPhar (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GenPhar
GenPhar was founded in 1999 and raised its 1st funding round 9 years after it was founded.
GenPhar is headquartered in Mount Pleasant, United States.
GenPhar was founded in 1999 in Mount Pleasant, United States. Operations center on the biotechnology sector, where vaccines and therapies for rare diseases are developed. Emphasis is placed on biodefense, prophylactic, and therapeutic vaccines directed at dangerous viral diseases. The product line encompasses drug resistance testing, vaccine development, and cancer treatments, supporting advancements in medical countermeasures.
GenPhar's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
GenPhar has 1 investor. Key investors include HHS.